Stock Track | OPKO Health Surges 7.64% Pre-market on Regeneron Collaboration for Multispecific Antibodies

Stock Track

Oct 29, 2025

OPKO Health (OPK) stock soared 7.64% in pre-market trading on Wednesday, following a significant announcement regarding a new research collaboration. The biotechnology company's shares reacted positively to news of its subsidiary, Modex Therapeutics, entering into a partnership with industry giant Regeneron.

The collaboration between Modex Therapeutics and Regeneron aims to develop multispecific antibodies for select therapeutic indications. This partnership represents a major step forward for OPKO Health, as it combines Modex's expertise with Regeneron's established presence in the biotechnology sector. Multispecific antibodies are at the forefront of modern therapeutic research, offering potential for more targeted and effective treatments across various diseases.

Investors appear to be optimistic about the potential outcomes of this collaboration. The development of new antibody therapies could open up significant revenue streams for OPKO Health in the future, while also enhancing its position in the competitive biotechnology market. As the pre-market surge indicates, the market views this partnership as a strong positive signal for OPKO Health's future prospects and innovative capabilities in the field of advanced therapeutics.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1170097761"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170097761\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170097761?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170097761","market":"us","top_or_hot":-1,"title":"Stock Track | OPKO Health Surges 7.64% Pre-market on Regeneron Collaboration for Multispecific Antibodies","media":"Stock Track","content":"<p>OPKO Health (OPK) stock soared 7.64% in pre-market trading on Wednesday, following a significant announcement regarding a new research collaboration. The biotechnology company's shares reacted positively to news of its subsidiary, Modex Therapeutics, entering into a partnership with industry giant Regeneron.</p>\n\n<p>The collaboration between Modex Therapeutics and Regeneron aims to develop multispecific antibodies for select therapeutic indications. This partnership represents a major step forward for OPKO Health, as it combines Modex's expertise with Regeneron's established presence in the biotechnology sector. Multispecific antibodies are at the forefront of modern therapeutic research, offering potential for more targeted and effective treatments across various diseases.</p>\n\n<p>Investors appear to be optimistic about the potential outcomes of this collaboration. The development of new antibody therapies could open up significant revenue streams for OPKO Health in the future, while also enhancing its position in the competitive biotechnology market. As the pre-market surge indicates, the market views this partnership as a strong positive signal for OPKO Health's future prospects and innovative capabilities in the field of advanced therapeutics.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | OPKO Health Surges 7.64% Pre-market on Regeneron Collaboration for Multispecific Antibodies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | OPKO Health Surges 7.64% Pre-market on Regeneron Collaboration for Multispecific Antibodies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-29 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>OPKO Health (OPK) stock soared 7.64% in pre-market trading on Wednesday, following a significant announcement regarding a new research collaboration. The biotechnology company's shares reacted positively to news of its subsidiary, Modex Therapeutics, entering into a partnership with industry giant Regeneron.</p>\n\n<p>The collaboration between Modex Therapeutics and Regeneron aims to develop multispecific antibodies for select therapeutic indications. This partnership represents a major step forward for OPKO Health, as it combines Modex's expertise with Regeneron's established presence in the biotechnology sector. Multispecific antibodies are at the forefront of modern therapeutic research, offering potential for more targeted and effective treatments across various diseases.</p>\n\n<p>Investors appear to be optimistic about the potential outcomes of this collaboration. The development of new antibody therapies could open up significant revenue streams for OPKO Health in the future, while also enhancing its position in the competitive biotechnology market. As the pre-market surge indicates, the market views this partnership as a strong positive signal for OPKO Health's future prospects and innovative capabilities in the field of advanced therapeutics.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPK","symbol_name":"Opko Health","start_time":0,"source_url":"","article_id":"1170097761","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170097761","pubTimestamp":1761739482,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"OPKO Health (OPK) stock soared 7.64% in pre-market trading on Wednesday, following a significant announcement regarding a new research collaboration. The biotechnology company's shares reacted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OPK":"Opko Health"},"translate_title":"股票追踪|OPKO Health盘前大涨7.64%因再生元合作开发多特异性抗体","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPK":1},"content_text":"OPKO Health (OPK) stock soared 7.64% in pre-market trading on Wednesday, following a significant announcement regarding a new research collaboration. The biotechnology company's shares reacted positively to news of its subsidiary, Modex Therapeutics, entering into a partnership with industry giant Regeneron.\nThe collaboration between Modex Therapeutics and Regeneron aims to develop multispecific antibodies for select therapeutic indications. This partnership represents a major step forward for OPKO Health, as it combines Modex's expertise with Regeneron's established presence in the biotechnology sector. Multispecific antibodies are at the forefront of modern therapeutic research, offering potential for more targeted and effective treatments across various diseases.\nInvestors appear to be optimistic about the potential outcomes of this collaboration. The development of new antibody therapies could open up significant revenue streams for OPKO Health in the future, while also enhancing its position in the competitive biotechnology market. As the pre-market surge indicates, the market views this partnership as a strong positive signal for OPKO Health's future prospects and innovative capabilities in the field of advanced therapeutics.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}